Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Linda L. Marcusson"'
Publikováno v:
PLoS Pathogens, Vol 5, Iss 8, p e1000541 (2009)
Fluoroquinolones are antibacterial drugs that inhibit DNA Gyrase and Topoisomerase IV. These essential enzymes facilitate chromosome replication and RNA transcription by regulating chromosome supercoiling. High-level resistance to fluoroquinolones in
Externí odkaz:
https://doaj.org/article/bfd5b24c19734804ac922aec2f27873b
Autor:
Jessica Bergman, Douglas L. Huseby, Diarmaid Hughes, Anna Zorzet, Gerrit Brandis, Franziska Pietsch, Linda L. Marcusson
Publikováno v:
Journal of Antimicrobial Chemotherapy. 72:75-84
Resistance to the fluoroquinolone drug ciprofloxacin is commonly linked to mutations that alter the drug target or increase drug efflux via the major AcrAB-TolC transporter. Very little is known about other mutations that might also reduce susceptibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62170f25180aee17eb65911e1a981591
https://doi.org/10.1093/jac/dkw364
https://doi.org/10.1093/jac/dkw364
Publikováno v:
Journal of Antimicrobial Chemotherapy. 60:795-801
The worldwide increase in antibiotic resistance is a concern for public health. When the appropriate antibiotic dosage is determined, the priorities are efficacy and toxicity. The aim of this thesis was to gain knowledge about the most efficient dosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2968961237dce52c71ad3c4df3a658d
https://doi.org/10.1093/jac/dkm265
https://doi.org/10.1093/jac/dkm265
Publikováno v:
International journal of antimicrobial agents. 44(4)
Pharmacodynamic and mutant prevention properties of the fluoroquinolone pradofloxacin (PRA) were measured against a set of 17 Escherichia coli strains carrying no, one or two known mutations conferring reduced fluoroquinolone susceptibility. The stra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8608ee8e492a85e036764bbc39e785e3
https://pubmed.ncbi.nlm.nih.gov/25129317
https://pubmed.ncbi.nlm.nih.gov/25129317
Publikováno v:
PLoS Pathogens
PLoS Pathogens, Vol 5, Iss 8, p e1000541 (2009)
PLoS Pathogens, Vol 5, Iss 8, p e1000541 (2009)
Fluoroquinolones are antibacterial drugs that inhibit DNA Gyrase and Topoisomerase IV. These essential enzymes facilitate chromosome replication and RNA transcription by regulating chromosome supercoiling. High-level resistance to fluoroquinolones in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a10088c7cf16839e0eab0fc2457d6abc
http://europepmc.org/articles/PMC2714960
http://europepmc.org/articles/PMC2714960
Publikováno v:
The Journal of antimicrobial chemotherapy. 57(6)
To evaluate the mutant prevention concentrations (MPCs) of ciprofloxacin for two susceptible and one first-step gyrA resistant mutant Escherichia coli strains in an in vitro kinetic model and to identify the pharmacodynamic index that best predicts p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24bd557db7b102d26c60f3e9a4038bde
https://pubmed.ncbi.nlm.nih.gov/16624874
https://pubmed.ncbi.nlm.nih.gov/16624874
Autor:
Niels Frimodt-Møller, Diarmaid Hughes, Dorthe Sandvang, Patricia Komp Lindgren, Linda L. Marcusson
Resistance to fluoroquinolones in urinary tract infection (UTIs) caused by Escherichia coli is associated with multiple mutations, typically those that alter DNA gyrase and DNA topoisomerase IV and those that regulate AcrAB-TolC-mediated efflux. We a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::234c1d1d1419f40374e084c89275ca3b
https://europepmc.org/articles/PMC1140522/
https://europepmc.org/articles/PMC1140522/
Publikováno v:
The Journal of antimicrobial chemotherapy. 55(6)
Antibiotic-resistant bacteria are increasingly a major healthcare problem but very few new classes of antibiotics have been discovered or launched in recent decades. Approaches to dealing with the problem include learning how bacteria evolve to resis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a566abc123a87fbc20d04be214648355
https://pubmed.ncbi.nlm.nih.gov/15860549
https://pubmed.ncbi.nlm.nih.gov/15860549
Publikováno v:
Journal of Antimicrobial Chemotherapy (JAC); Jun2006, Vol. 57 Issue 6, p1116-1121, 6p
Publikováno v:
Journal of Antimicrobial Chemotherapy (JAC); Jun2005, Vol. 55 Issue 6, p938-943, 6p